Select committee angry over absence of drug regulator from sessionBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7485.214-c (Published 27 January 2005) Cite this as: BMJ 2005;330:214
- Lynn Eaton
Members of the House of Commons select committee on health appeared angry that they were not able to question one of the employees of the United Kingdom's drug regulatory authority at a session last week looking into the influence of the drug industry.
Although several senior figures from the Medicines and Healthcare Products Regulatory Agency attended the session, the committee said that it would also have liked to have heard evidence from Ian Hudson. Dr Hudson is a member of the agency's executive board and was worldwide director of safety at SmithKline Beecham from 1999 to 2001, having worked forthe company since …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial